Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis

Phase 1/2 Completed 57 enrolled UnicoCell Biomed CO. LTD A2 Healthcare Taiwan Corporation · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

1. To assess the safety of allogeneic injection of expanded ADSCs to patients with knee osteoarthritis 2. To assess the efficacy of allogeneic injection of expanded ADSCs to patients with knee osteoarthritis

Timeline

Start: 2016-03
Primary completion: 2018-07
Completion: 2021-06

Publications

Chen CF, Hu CC, Wu CT, Wu HH, Chang CS, Hung YP, Tsai CC, Chang Y. Treatment of knee osteoarthritis with intra-articular injection of allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE(R): a phase I/II, randomized, active-control, single-blind, multiple-center clinical trial. Stem Cell Res Ther. 2021 Oct 30;12(1):562. doi: 10.1186/s13287-021-02631-z.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ELIXCYTE	Cell therapy	2 ml	Other
Subject	ELIXCYTE	Cell therapy	4 ml	Other
Subject	ELIXCYTE	Cell therapy	8 ml	Other
Subject	ELIXCYTE	Cell therapy	1.6e+07 cells	Other
Subject	ELIXCYTE	Cell therapy	3.2e+07 cells	Other
Subject	ELIXCYTE	Cell therapy	6.4e+07 cells	Other

Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis

Summary

Timeline

Publications

Drugs

Indications